Guilherme das Posses Bridi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guilherme das Posses Bridi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Guedes Baldi
Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sâo Paulo, Sâo Paulo, Brazil
9 shared publications - Ronaldo Adib Kairalla
Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sâo Paulo, Sâo Paulo, Brazil
6 shared publications - Carlos Roberto Ribeiro Carvalho
Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sâo Paulo, Sâo Paulo, Brazil
3 shared publications - Celso Ricardo Fernandes Carvalho
University of São Paulo
2 shared publications - Ellen Caroline Toledo Do Nascimento
Department of Pathology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil
2 shared publications - João Marcos Salge
Divisão de Pneumologia, Instituto do Coração - InCor - Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil
2 shared publications
Latest Publications
- Open Access
- 11 September 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (1)
Mechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis
Background: Hypersensitivity pneumonitis (HP) is an immune-mediated condition triggered by inhaled antigens in susceptible individuals. Patients with HP often present with exercise limitation due to multiple mechanisms, including ventilatory and cardiocirculatory impairments, particularly pulmonary hypertension (PH). Methods: In this cross-sectional study, patients with HP of varying severity underwent clinical assessment, including quality-of-life questionnaires, incremental treadmill cardiopulmonary exercise testing (CPET), pulmonary function testing, 6-min walk test and transthoracic echocardiography (TTE). Patients with a diffusing capacity of the lung for carbon monoxide ( D LCO ) below 40% of predicted and/or a tricuspid regurgitation velocity >2.5 m·s −1 or pulmonary artery systolic pressure >35 mmHg on TTE were referred for right heart catheterisation. Results: Among 90 patients, 65% were female, with a median age of 65.5 years, and 85% had fibrotic HP. CPET was performed in 51 patients (56%), with a mean peak oxygen consumption of 58±13% of predicted. Exercise capacity was reduced in 98% of patients, with multifactorial limitation in 88%, primarily due to cardiocirculatory impairment (76%) and impaired gas exchange (66%). The mean 6-min walk distance was 334±116 m. Mean forced vital capacity and D LCO were 56±20% and 42±22% predicted, respectively. PH was identified in 59% of patients (95% CI 48–72%), predominantly with combined post- and pre-capillary involvement. Conclusions: Reduced exercise capacity is highly prevalent in patients with HP and is typically multifactorial. PH is also common, with a predominance of combined post- and pre-capillary patterns. These findings underscore the need for a comprehensive evaluation strategy in symptomatic HP patients.
- 11 September 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (1)
Open AccessMechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis
Background: Hypersensitivity pneumonitis (HP) is an immune-mediated condition triggered by inhaled antigens in susceptible individuals. Patients with HP often present with exercise limitation due to multiple mechanisms, including ventilatory and cardiocirculatory impairments, particularly pulmonary hypertension (PH). Methods: In this cross-sectional study, patients with HP of varying severity underwent clinical assessment, including quality-of-life questionnaires, incremental treadmill cardiopulmonary exercise testing (CPET), pulmonary function testing, 6-min walk test and transthoracic echocardiography (TTE). Patients with a diffusing capacity of the lung for carbon monoxide ( D LCO ) below 40% of predicted and/or a tricuspid regurgitation velocity >2.5 m·s −1 or pulmonary artery systolic pressure >35 mmHg on TTE were referred for right heart catheterisation. Results: Among 90 patients, 65% were female, with a median age of 65.5 years, and 85% had fibrotic HP. CPET was performed in 51 patients (56%), with a mean peak oxygen consumption of 58±13% of predicted. Exercise capacity was reduced in 98% of patients, with multifactorial limitation in 88%, primarily due to cardiocirculatory impairment (76%) and impaired gas exchange (66%). The mean 6-min walk distance was 334±116 m. Mean forced vital capacity and D LCO were 56±20% and 42±22% predicted, respectively. PH was identified in 59% of patients (95% CI 48–72%), predominantly with combined post- and pre-capillary involvement. Conclusions: Reduced exercise capacity is highly prevalent in patients with HP and is typically multifactorial. PH is also common, with a predominance of combined post- and pre-capillary patterns. These findings underscore the need for a comprehensive evaluation strategy in symptomatic HP patients.
- 6 May 2025
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- p. 1-15
Mechanisms of exercise limitation and pulmonary rehabilitation in patients with cystic lung diseases
The main diffuse cystic lung diseases (DCLD) include lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), Birt-Hogg-Dubé syndrome, and lymphocytic interstitial pneumonia. Exercise limitationis frequent and secondary to multiple mechanisms in DCLD. Some studies addressed mechanisms for exercise limitation, field tests, and pulmonary rehabilitation (PR) in DCLD. This review aims to present the main mechanisms that determine exercise limitation, the responses of patients in field tests, and the details regarding the safety and efficacy of PR in DCLD, with emphasis on LAM and PLCH. A search on the issue was performed in the MEDLINE and SciELO databases between 27 November 2024 and 20 February 2025. Manuscripts were reviewed and important topics were included in this review. Reduced exercise capacity is common and multifactorial, including ventilatory, cardiocirculatory, and peripheral limitations, pulmonary hypertension (PH), and impaired gas exchange in LAM and PLCH. Variables from field tests are correlated with pulmonary function tests, and PR is safe and beneficial in LAM. Further studies are necessary to evaluate exercise in other DCLDs, the impact of other therapeutic modalities on DH, hypoxemia, and exercise-induced PH in LAM and PLCH, and the safety and benefits of PR mostly in PLCH.
- 6 May 2025
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- p. 1-15
Mechanisms of exercise limitation and pulmonary rehabilitation in patients with cystic lung diseases
The main diffuse cystic lung diseases (DCLD) include lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), Birt-Hogg-Dubé syndrome, and lymphocytic interstitial pneumonia. Exercise limitationis frequent and secondary to multiple mechanisms in DCLD. Some studies addressed mechanisms for exercise limitation, field tests, and pulmonary rehabilitation (PR) in DCLD. This review aims to present the main mechanisms that determine exercise limitation, the responses of patients in field tests, and the details regarding the safety and efficacy of PR in DCLD, with emphasis on LAM and PLCH. A search on the issue was performed in the MEDLINE and SciELO databases between 27 November 2024 and 20 February 2025. Manuscripts were reviewed and important topics were included in this review. Reduced exercise capacity is common and multifactorial, including ventilatory, cardiocirculatory, and peripheral limitations, pulmonary hypertension (PH), and impaired gas exchange in LAM and PLCH. Variables from field tests are correlated with pulmonary function tests, and PR is safe and beneficial in LAM. Further studies are necessary to evaluate exercise in other DCLDs, the impact of other therapeutic modalities on DH, hypoxemia, and exercise-induced PH in LAM and PLCH, and the safety and benefits of PR mostly in PLCH.
- Open Access
- 21 November 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (5) , e20240192
Acid sphingomyelinase deficiency with homozygous p.Arg610del genotype in an elderly patient: a rare case report
- 21 November 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (5) , e20240192
Open AccessAcid sphingomyelinase deficiency with homozygous p.Arg610del genotype in an elderly patient: a rare case report
- Open Access
- 18 September 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (4) , e20240110
Drug-induced lung disease: a narrative review
Drug-induced lung disease (DILD) encompasses a broad, highly heterogeneous group of conditions that may occur as a result of exposure to numerous agents, such as antineoplastic drugs, conventional or biological disease-modifying antirheumatic drugs, antiarrhythmics, and antibiotics. Between 3% and 5% of prevalent cases of interstitial lung diseases are reported as DILDs. The pathogenesis of lung injury in DILD is variable, multifactorial, and often unknown. Acute presentation is the most common, can occur from days to months after the start of treatment, and ranges from asymptomatic to acute respiratory failure. The CT patterns are varied and include ground-glass opacities, organizing pneumonia, and diffuse alveolar damage. Notably, there are no clinical manifestations or CT patterns specific to DILD, which makes the diagnosis quite challenging and necessitates a high index of suspicion, as well as the exclusion of alternative causes such as infection, cardiac-related pulmonary edema, exacerbation of a preexisting ILD, and neoplastic lung involvement. Discontinuation of the offending medication constitutes the cornerstone of treatment, and corticosteroid treatment is usually necessary after the onset of clinical manifestations. The prognosis varies widely, with high mortality rates in severe cases. A history of medications related to pulmonary toxicity in patients with new-onset respiratory symptoms should prompt consideration of DILD as a potential underlying cause.
- 18 September 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (4) , e20240110
Open AccessDrug-induced lung disease: a narrative review
Drug-induced lung disease (DILD) encompasses a broad, highly heterogeneous group of conditions that may occur as a result of exposure to numerous agents, such as antineoplastic drugs, conventional or biological disease-modifying antirheumatic drugs, antiarrhythmics, and antibiotics. Between 3% and 5% of prevalent cases of interstitial lung diseases are reported as DILDs. The pathogenesis of lung injury in DILD is variable, multifactorial, and often unknown. Acute presentation is the most common, can occur from days to months after the start of treatment, and ranges from asymptomatic to acute respiratory failure. The CT patterns are varied and include ground-glass opacities, organizing pneumonia, and diffuse alveolar damage. Notably, there are no clinical manifestations or CT patterns specific to DILD, which makes the diagnosis quite challenging and necessitates a high index of suspicion, as well as the exclusion of alternative causes such as infection, cardiac-related pulmonary edema, exacerbation of a preexisting ILD, and neoplastic lung involvement. Discontinuation of the offending medication constitutes the cornerstone of treatment, and corticosteroid treatment is usually necessary after the onset of clinical manifestations. The prognosis varies widely, with high mortality rates in severe cases. A history of medications related to pulmonary toxicity in patients with new-onset respiratory symptoms should prompt consideration of DILD as a potential underlying cause.
- Open Access
- 10 March 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (2) , 195-197
Thoracic endometriosis presenting as diffuse cystic lung disease: a rare case report
- 10 March 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (2) , 195-197
Open AccessThoracic endometriosis presenting as diffuse cystic lung disease: a rare case report
Twenty-year-old patient with polyarthritis since childhood showing cysts and ground glass attenuation on HRCT
High-resolution CT (HRCT) showed cysts and ground glass with reticular infiltrates (figure 1A-D). In 2006, she underwent a pulmonary biopsy, which revealed follicular bronchiolitis (figure 2A-D), without features of haemorrhage on biopsy such as haemosiderin laden macrophages.
Twenty-year-old patient with polyarthritis since childhood showing cysts and ground glass attenuation on HRCT
High-resolution CT (HRCT) showed cysts and ground glass with reticular infiltrates (figure 1A-D). In 2006, she underwent a pulmonary biopsy, which revealed follicular bronchiolitis (figure 2A-D), without features of haemorrhage on biopsy such as haemosiderin laden macrophages.
- Open Access
- 27 November 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (6) , e20230317
Nephrobronchial fistula: a diagnostic challenge in a patient with IgG4-related disease
- 27 November 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (6) , e20230317
Open AccessNephrobronchial fistula: a diagnostic challenge in a patient with IgG4-related disease
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A6341
Thoracic Endometriosis Presented as Diffuse Cystic Lung Disease: A Rare Case Report
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A6341
Thoracic Endometriosis Presented as Diffuse Cystic Lung Disease: A Rare Case Report
- Open Access
- 25 January 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (1) , 20220466e
Tomographic pleuropulmonary manifestations in rheumatoid arthritis: a pictorial essay
Rheumatoid arthritis (RA) is an autoimmune inflammatory and heterogeneous disease that affects several systems, especially the joints. Among the extra-articular manifestations of RA, pleuropulmonary involvement occurs frequently, with different presentations, potentially in all anatomic thoracic compartments, and may determine high morbidity and mortality. The most common pleuropulmonary manifestations in patients with RA include interstitial lung disease (ILD), pleural disease, pulmonary arterial hypertension, rheumatoid lung nodules, airway disease (bronchiectasis and bronchiolitis), and lymphadenopathy. Pulmonary hypertension and ILD are the manifestations with the greatest negative impact in prognosis. HRCT of the chest is essential in the evaluation of patients with RA with respiratory symptoms, especially those with higher risk factors for ILD, such as male gender, smoking, older age, high levels of rheumatoid factor, or positive anti-cyclic citrullinated peptide antibody results. Additionally, other etiologies that may determine tomographic pleuropulmonary manifestations in patients with RA are infections, neoplasms, and drug-induced lung disease. In these scenarios, clinical presentation is heterogeneous, varying from being asymptomatic to having progressive respiratory failure. Knowledge on the potential etiologies causing tomographic pleuropulmonary manifestations in patients with RA coupled with proper clinical reasoning is crucial to diagnose and treat these patients.
- 25 January 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (1) , 20220466e
Open AccessTomographic pleuropulmonary manifestations in rheumatoid arthritis: a pictorial essay
Rheumatoid arthritis (RA) is an autoimmune inflammatory and heterogeneous disease that affects several systems, especially the joints. Among the extra-articular manifestations of RA, pleuropulmonary involvement occurs frequently, with different presentations, potentially in all anatomic thoracic compartments, and may determine high morbidity and mortality. The most common pleuropulmonary manifestations in patients with RA include interstitial lung disease (ILD), pleural disease, pulmonary arterial hypertension, rheumatoid lung nodules, airway disease (bronchiectasis and bronchiolitis), and lymphadenopathy. Pulmonary hypertension and ILD are the manifestations with the greatest negative impact in prognosis. HRCT of the chest is essential in the evaluation of patients with RA with respiratory symptoms, especially those with higher risk factors for ILD, such as male gender, smoking, older age, high levels of rheumatoid factor, or positive anti-cyclic citrullinated peptide antibody results. Additionally, other etiologies that may determine tomographic pleuropulmonary manifestations in patients with RA are infections, neoplasms, and drug-induced lung disease. In these scenarios, clinical presentation is heterogeneous, varying from being asymptomatic to having progressive respiratory failure. Knowledge on the potential etiologies causing tomographic pleuropulmonary manifestations in patients with RA coupled with proper clinical reasoning is crucial to diagnose and treat these patients.
- 13 August 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 59 (2) , 69-70
Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We?
- 13 August 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 59 (2) , 69-70
Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We?